Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 5;8:13236. doi: 10.1038/s41598-018-31653-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effects of APOE mutation. (A) When GLM was used, no significant effects of APOE genotype in subject scores were observed in any groups (p > 0.08, student t-test), which was replicated when SSM/PCA was used (p > 0.06). (B) The proportion of subjects classified as “AD” vs. “non-AD” by SVM-ISDA was significantly different between APOE ɛ4 carriers vs. non-carriers only in stable MCI patients (χ² = 7.202, p = 0.007, Pearson Chi-Square). In other words, if a patient with stable MCI has ɛ4, it is more likely that the patient will be classified as “AD”. From the 118 stable MCI non-ɛ4 carriers, 21 patients (17.8%) were classified as AD, in contrast to 24 of 68 stable MCI ɛ4 carriers (35.3%) were classified as AD. Similar results were produced when SVM-SMO was used in stable MCI patients (χ² = 10.690, p = 0.001). In contrast, 8–10% normal control subjects received AD-designation regardless of APOE status. In AD, 86–88% individuals received AD-designation regardless of APOE status. In prodromal AD, 61–72% individuals received AD-designation regardless of APOE status.